Journals / European Journal of Rheumatology / 2015 / Cilt: 2 - Sayı: 3

Propiltiourasile baslı alveoler hemoraji: vaka sunumu

Propylthiouracil-induced alveolar hemorrhage

Pages
114–116
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We present here a case of alveolar hemorrhage induced by propilthiouracil (PTU) during treatment with PTU for Graves disease; patients completely recovered with corticosteroid, cyclophosphamide, and plasmapheresis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Thionamide induced vasculitis is a multisystem disease.
📊
Key Findings & Data:The patients may present with different clinical signs and findings due to organ involvement.
💡
Conclusion & Impact:We present here a case of alveolar hemorrhage induced by propilthiouracil (PTU) during treatment with PTU for Graves disease; patients completely recovered with corticosteroid, cyclophosphamide, and plasmapheresis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Thionamide induced vasculitis is a multisystem disease. The patients may present with different clinical signs and findings due to organ involvement. These patients are almost always perinuclear antineutrophil cytoplasmic antibody (pANCA) or antimyeloperoxidase (MPO) positive. Clinical findings are not seen in all of the patients who are ANCA positive while using thionamide. Although symptoms usually resolve with drug discontinuation, some patients, however, require high-dose steroids, immunosuppressants, or plasmapheresis. We present here a case of alveolar hemorrhage induced by propilthiouracil (PTU) during treatment with PTU for Graves disease; patients completely recovered with corticosteroid, cyclophosphamide, and plasmapheresis.

Özet

Tiyonamidin neden olduğu vaskülit multi-sistem bir hastalıktır. Organ tutulumundan dolayı hastalar farklı klinik şikayetler ve bulgularla başvurabilirler. Bu hastalarda hemen hemen her zaman perinükleer anti-nötrofil sitoplazmik antikor (p-ANCA) veya anti-miyeloperoksidaz (MPO) pozitifliği görülür. Tiyonamid kullanırken ANCA pozitifliği olan hastaların hepsinde klinik bulgulara rastlanır. Semptomların genellikle ilacın kesilmesi ile ortadan kalkmasına rağmen, bazı hastalar yüksek doz steroidler, immünosüpresanlara veya plazmaferezlere ihtiyaç duyarlar. Bu çalışmada, Graves hastalığı için verilen propiltiourasil (PTU) tedavisi sırasında PTUya bağlı alveolar hemorajinin geliştiği bir vaka sunulmaktadır. Hastalar kortikosteroid, siklofosfamid ve plazmaferez ile tamamen iyileşmişlerdir.

🔖

Cite This Article

ŞAHİN, M., AYDIN, B., KALE, B. K., AKSU, O., KACEMER, H., DEMİRKAN, H., ALTUNTAŞ, A., DİRİCAN, N. (2022). Propiltiourasile baslı alveoler hemoraji: vaka sunumu. European Journal of Rheumatology, Cilt: 2 - Sayı: 3, 114–116. https://ajindex.com/articles/511837

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Vanek C, Samuels MH. Central nervous system vasculitis caused by propylthiouracil therapy. Thyroid 2005; 15: 80-4. [CrossRef] 2. Dolman KM, Gans RO, Vervaat TJ, Zevenbergen G, Maingay D, Nikkels RE, et al. Vasculitis & antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 1993; 342: 651-2. [CrossRef] 3. Pillinger M, Staud R. Wegener’s granulomatosis in a patient receiving propylthiouracil for Graves disease. Semin Arthritis Rheum. 1998; 28: 124-29. [CrossRef] 4. Cooper DS. Antithyroid drugs. N Engl J Med 2005; 352: 905-17. [CrossRef] 5. Kimura S, Ikeda-Saito M. Human myeloperoxidase and thyroid peroxidase, two enzymes with separate and distinct physiological functions, are evolutionarily related members of the same gene family. Proteins 1988; 3: 113- 120. [CrossRef] 6. Haapala AM, Hyoty H, Parkkonen P, Mustonen J, Soppi E. Antibody reactivity against thyroid peroxidase and myeloperoxidase in autoimmune thyroiditis and systemic vasculitis. Scand J Immunol 1997; 46: 78-85. [CrossRef] 7. Jiang X, Khursigara G, Rubin RL. Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science 1994; 266: 810-3. [CrossRef] 8. Von Schmiedeberg S, Goebel C, Gleichmann E, Uetrecht J. Neutrophils and drug metabolism [letter] Science 1995; 268: 585-6. [CrossRef] 9. Lee E, Miki Y, Katsura H, Kariya K. Mechanism of inactivation of myeloperoxidase by propylthiouracil. Biochem Pharmacol 1990; 39: 1467-71. [CrossRef] 10. Gunton JE, Stiel J, Caterson RJ, McElduff A. Clinical case seminar: Anti-thyroid drugs and antineutrophil cytoplasmic antibody positive vasculitis. A case report and review of the literature. J Clin Endocrinol Metab 1999; 84: 13-6. [CrossRef] 11. Noh JY, Asari T, Hamada N, Makino F, Ishikawa N, Abe Y, et al. Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPOANCA) in Graves’ disease patients treated with propylthiouracil & the relationship between MPO-ANCA and clinical manifestations. Clin Endocrinol 2001; 54: 651-4. [CrossRef]